Solution for injection - 50 mg / 2 ml
Ranitidine is an antagonist of the histamine H2-receptor that assists in the treatment of gastric and duodenal ulcers by inhibiting secretion of hydrochloric acid as a result of H2 receptor blocking.
Prodrenitid is indicated:
- in the treatment of duodenal ulcer and benign gastric ulcer, including that caused by non-steroidal anti-inflammatory agents;
- in the treatment of gastro-oesophageal reflux disease;
- in Zollinger-Ellison syndrome;
- in ulceration caused by stress;
- as prophylaxis of recurrent haemorrhage with bleeding peptic ulcers.
Sugar-coated tablets – 10 mg
Solution for injection - (0.1%) 1 mg/1 ml
Tablets - 500 mg
Solution for injection - (0.1%) 1 mg/1 ml
Film-coated tablets – 600 mg
